Doptelet

RSS

avatrombopag

Authorised
This medicine is authorised for use in the European Union.

Overview

Doptelet is a medicine used to prevent excessive bleeding in adults with thrombocytopenia due to long-standing liver disease. Patients with thrombocytopenia have reduced number of platelets (components in the blood that help it to clot), which can cause excessive bleeding.

The medicine is for use in patients having an invasive procedure (a medical procedure that involves cutting into or puncturing the skin or inserting instruments into the body).

Doptelet contains the active substance avatrombopag.

This EPAR was last updated on 25/06/2019

Authorisation details

Product details
Name
Doptelet
Agency product number
EMEA/H/C/004722
Active substance
avatrombopag
International non-proprietary name (INN) or common name
avatrombopag
Therapeutic area (MeSH)
Thrombocytopenia
Anatomical therapeutic chemical (ATC) code
B02BX
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Dova Pharmaceuticals Ireland Limited
Contact address

6th Floor, 2 Grand Canal Square
Dublin 2, D02 A342
Ireland

Product information

20/06/2019 Doptelet - EMEA/H/C/004722 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antihemorrhagics

Therapeutic indication

Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.

Assessment history

How useful was this page?

Add your rating